Maharashtra FDA cancels Cipla Pune warehouse sale licence; Cipla contests order
Maharashtra FDA has cancelled the drug sale licence of Cipla Pharma & Life Sciences’ Pune C&F warehouse, citing alleged packaging, storage, labelling and recall-compliance lapses involving Reactin Plus Tablets. Cipla says the order does not allege any product-quality or patient-safety issue and is under judicial challenge.
What happened
Maharashtra FDA cancelled Cipla Pharma & Life Sciences’ Pune C&F warehouse drug sale licence over alleged packaging, storage, labelling and recall
Key facts
- August 27
- March 2026
Why this matters
The episode highlights regulatory diligence risk in pharmaceutical supply-chain assets, making warehouse compliance systems, licence status and recall controls central to any partnership or transaction assessment.
What to watch
- Court decision on Cipla's challenge, especially any interim stay or conditions attached to continued operations.
- Evidence of stock-outs, order delays, or distributor disruption for Reactin Plus or other Pune-warehouse supplied products.
- Whether Maharashtra FDA identifies product-quality, safety, adulteration, or recall-execution concerns beyond the currently described operational lapses.
- Any show-cause notices, inspections, or licence actions involving Cipla's other warehouses, manufacturing plants, or products.
- Cipla disclosures on remediation costs, alternate-logistics arrangements, inventory write-offs, or revenue impact.
- Seek an interim stay from the relevant court and contest the cancellation order on procedural and factual grounds.
- Activate alternate distribution routes and communicate supply-continuity plans to distributors, pharmacies, hospitals, and key trade partners.
- Complete a documented corrective and preventive action plan covering packaging controls, storage conditions, labelling checks, recall traceability, and warehouse training.
- Conduct a network-wide internal audit of comparable C&F warehouses to identify similar compliance gaps before regulators do.
- Provide investors with clarity on affected products, inventory availability, financial exposure, and whether the issue has implications beyond the Pune facility.